MORGAN STANLEY - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 110 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.

Quarter-by-quarter ownership
MORGAN STANLEY ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$327,823
+52.7%
277,816
+82.5%
0.00%
Q2 2023$214,643
-53.3%
152,229
-50.3%
0.00%
Q1 2023$459,180
+197.8%
306,120
+132.3%
0.00%
Q4 2022$154,197
+120.3%
131,793
+110.7%
0.00%
Q3 2022$70,000
-65.5%
62,562
-51.5%
0.00%
Q2 2022$203,000
-46.0%
128,905
-47.2%
0.00%
Q1 2022$376,000
-71.0%
244,155
-53.8%
0.00%
Q4 2021$1,295,000
+309.8%
528,557
+321.7%
0.00%
Q3 2021$316,000
-13.9%
125,343
-2.7%
0.00%
Q2 2021$367,000
+41.7%
128,762
+16.5%
0.00%
Q1 2021$259,000
+13.6%
110,527
-14.8%
0.00%
Q4 2020$228,000
+356.0%
129,670
+142.9%
0.00%
Q3 2020$50,000
-31.5%
53,383
-36.9%
0.00%
Q2 2020$73,000
+52.1%
84,546
+44.9%
0.00%
Q1 2020$48,000
-72.6%
58,348
-70.4%
0.00%
Q4 2019$175,000
+130.3%
197,324
+152.9%
0.00%
Q3 2019$76,00078,0220.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders